241 results about "Circadian rhythm" patented technology

A method and system for monitoring and / or controlling a glycemic state of a subject, comprising a housing device having one or more chambers, extendable and retractable sensors, extendable and retractable catheters, insulin reservoir, neuroprotective agent reservoir, release mechanism for releasing insulin and neuroprotective agent into the subject, and a control mechanism with a processor for receiving and analyzing outputs from the sensors and for controlling the release mechanism, a clock mechanism for providing logging and / or circadian information to the processor, an internal analysis chamber, a byproduct storage chamber, a sampling mechanism, a transfer mechanism, a self-sealing membrane, a calibration chamber, a replacement sensor chamber, a prevention mechanism to prevent deposition of unwanted substances on a sensor or catheter, a removal mechanism to remove unwanted substances from a sensor or catheter, a warning mechanism, a real-time clock and non-volatile memory to store and log information processed by the processor, a failure detection mechanism, and wired and / or wireless communication linkages both internally and externally.

A corneal inlay protects ocular structures from harmful wavelengths of light while maintaining acceptable color cosmetics, color perception, overall light transmission, photopic vision, scotopic vision, color vision, and / or cirdadian rhythms. The corneal inlay can also include a pinhole effect to increase depth of focus. In some embodiments, the corneal inlay can also correct refractive errors including, but not limited to, higher order aberration, lower order aberration, myopia, hyperopia, astigmatism, and / or presbyopia.

Techniques are provided for detecting the circadian state of a patient using an implantable medical device based on selected blood carbon dioxide (CO2) parameters. In one example, the implantable device tracks changes in end tidal CO2 (etCO2) levels and changes in maximum variations of pCO2 levels per breathing cycle (ΔcycleCO2) over the course of the day and determines the circadian state based thereon. It has been found that average etCO2 levels are generally highest and average ΔcycleCO2 levels are generally lowest while a patient is asleep and opposite while a patient is awake. Hence, by tracking changes in average etCO2 and ΔcycleCO2 levels over the course of the day, circadian states can be detected. Minute ventilation and activity levels are used to assist in the determination of the circadian state. Additional techniques are directed to detecting the stage of sleep.

Systems and methods for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and treating hyperglycemia, Alzheimer's disease, sleep disorders, Parkinson's disease, Attention Deficit Disorder and nicotine addiction involve synchronizing and tailoring the administration of nutraceuticals, medications and other substances (for example, stimulants) in accordance with the body's natural circadian rhythms, meal times and other factors. Improved control of blood glucose levels, extended alertness, and weight control, and counteracting of disease symptoms when they are at their worst are possible. An automated, pre-programmable transdermal administration system is used to provide pulsed doses of medications, pharmaceuticals, hormones, neuropeptides, anorexigens, pro-drugs, stimulants, plant extracts, botanicals, nutraceuticals, cosmeceuticals, phytochemicals, phytonutrients, enzymes, antioxidants, essential oils, fatty acids, minerals, vitamins, amino acids, coenzymes, or other physiological active ingredient or precursor. The system can utilize a pump, pressurized reservoir, a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with porous membranes or micro-fabricated structures.

Environmental characteristics of habitable environments (e.g., hotel or motel rooms, spas, resorts, cruise boat cabins, offices, hospitals and / or homes, apartments or residences) are controlled to eliminate, reduce or ameliorate adverse or harmful aspects and introduce, increase or enhance beneficial aspects in order to improve a “wellness” or sense of “wellbeing” provided via the environments. Control of intensity and wavelength distribution of passive and active Illumination addresses various issues, symptoms or syndromes, for instance to maintain a circadian rhythm or cycle, adjust for “jet lag” or season affective disorder, etc. Air quality and attributes are controlled. Scent(s) may be dispersed. Noise is reduced and sounds (e.g., masking, music, natural) may be provided. Environmental and biometric feedback is provided. Experimentation and machine learning are used to improve health outcomes and wellness standards.

This is a new invention, including improvements upon existing inventions, which is safer, simpler to use, less invasive into a user's daily routine and provides a lower cost solution to existing pulsed magnetic field and related vibrational electromagnetic therapy devices. This invention (apparatus) is referred to as an EnergyWave Therapy Device to distinguish it from existing electromagnetic therapy devices. It operates non-invasively on a homeopathic level to improve sleep, encourage natural healing and reduce pain, swelling, and general discomfort. This is accomplished through different embodiments of the apparatus all of which generate Multiple Simultaneous Extremely Low Frequency (MSELF) energy waves which may be any combination of Alternating Polarity Magnetic Fields (APMF), narrowband near-coherent long-wavelength (580 nm to 980 nm) light emitting diodes (LEDs), or electrical vibrations transmitted through the medium of water using carbon rod electrodes. The MSELF vibrations are derived from a quartz crystal with a fundamental frequency less than one-half of one percent from a natural Fibonacci Sequence Number. The apparatus utilizes firmware operating in a microcontroller containing predefined, user selectable therapy programs either emulating natural Circadian Rhythms for sleep and rest, or other therapeutic programs, all of which contain Electromagnetic Field (EMF) dose limitations to prevent any possible overexposure. The microcontroller is also clocked at the same fundamental frequency generated by the Fibonacci Sequence Quartz Crystal. Additionally, the apparatus's unique application of an H-Bridge configuration power-driver with Pulse Width Modulation (PWM) capabilities supports a novel approach to supply two simultaneous therapeutic frequencies to either a copper-trace coil emitter integrated on the main Printed Circuit Board (PCB) or optional external energy emitters. The result is a more effective, lower energy, safer, lower cost, simpler to use, noninvasive, multi-modal, EnergyWave Therapy Device.

The present invention relates to an artificial light system for modulating circadian rhythms, increasing vigilance and influencing light-associated psychological conditions such as seasonal affective disorder. The system of the invention comprises a source of a green and / or red light and a source of blue light both light sources being controlled by a computer to provide predetermined light conditions. More specifically, the computer is programmed to provide pulses of blue light and continuous or pulsed red light, to enhance the efficacy of blue light, reduce blue-light hazard and avoid stroboscopic effect.

A portable light delivery device for delivering light to the blood supply of a human body through a nonocular area of skin on the body includes an attachment member, a portable light delivery unit connected to the attachment member and a portable power supply. The portable light delivery unit provides one or more wavelengths of light within a specifically determined range of intensity and a specifically determined angle of illumination. A portable control unit may be included on the light delivery device for selectively controlling the light delivery unit. A programming device associated with the control unit selectively changes the programming of the controller. The light delivery device is portably secured to a region of the body having a substantial amount of blood vessels near the surface thereof to deliver light to the blood supply of the body for treating mood disorders, seasonal affective disorder and disorders involving circadian rhythm and sleep.

A method and system for monitoring and / or controlling a glycemic state of a subject, comprising a housing device having one or more chambers, extendable and retractable sensors, extendable and retractable catheters, insulin reservoir, neuroprotective agent reservoir, release mechanism for releasing insulin and neuroprotective agent into the subject, and a control mechanism with a processor for receiving and analyzing outputs from the sensors and for controlling the release mechanism, a clock mechanism for providing logging and / or circadian information to the processor.

This invention provides for an energized biomedical ophthalmic device and associated method of measuring changes in biomarkers contained in tear film to generate data related to a light therapy regimen used to treat symptoms associated with seasonal affective disorder. In some embodiments, the energized biomedical ophthalmic device can include an energized contact lens with a light source in communication with a processor controlling said light source according to the light therapy regimen. The light therapy regimen may be generated or modified by the processor from the measured changes and sometimes from user's preferences, and / or additional measurements, including for example, light exposure and / or circadian rhythm of the user.

A system and method of determining the status of an adverse cardiac condition of a medical patient based on circadian variation of one or more hemodynamic parameters are provided. In some embodiments, the system and method calculate a first average value of a series of first values during a first time period, a second average value of a series of second values during a second time period, and a difference between the first average value and the second average value. The method provides an indication of an adverse cardiac condition when the difference is less than a predetermined threshold.

Compositions and methods for enhancing repair of damaged DNA in skin cells. Topical compositions comprising at least one agent that upregulates circadian gene expression in skin cells and at least one non-circadian agent that delays mitosis in skin cells. Preferably, such compositions comprise one or more keratinocyte clock and per1 gene activators, along with SIRT1 or one or more sirt1 activators. More preferably, the sirt1 activator is a synergistic combination of specific peptidic sirt1 activators and resveratrol. Preferably, such compositions are easy to use, efficacious, cosmetically acceptable, chemically, thermodynamically and light stable, safe for topical use, have little or no side effects, and commercially feasible in a personal care marketplace.

This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and / or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.

Systems and methods for controlling environmental illumination relative to circadian function of individuals are provided. A method is provided for controlling the operation of light sources by assigning a circadian state to the individual based on received electronic information, extrapolating future circadian states based on the assigned circadian state, the assigned circadian state or the extrapolated future circadian states including at least a biological night state, and encoding machine-level control commands that control the operation of the light source for transmission to the light sources adapted for the biological night state by having circadian-significant attenuation along the circadian active wavelength range.

Techniques are provided for estimating left atrial pressure (LAP) or other cardiac pressure parameters based on various parameters derived from impedance signals. In particular, effective LAP is estimated based on one or more of: electrical conductance values, cardiogenic pulse amplitudes, circadian rhythm pulse amplitudes, or signal morphology fractionation values, each derived from the impedance signals detected by the implantable device. Predetermined conversion factors stored within the device are used to convert the various parameters derived from the electrical impedance signal into LAP values or other appropriate cardiac pressure values. The conversion factors may be, for example, slope and baseline values derived during an initial calibration procedure performed by an external system, such as an external programmer. In some examples, the slope and baseline values may be periodically re-calibrated by the implantable device itself.

A unit dosage form, such as a capsule or the like, for delivering drugs into the body in a circadian release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. Each bead population exhibits a pre-designed rapid or sustained release profile with or without a predetermined lag time of 3 to 5 hours. Such a circadian rhythm release drug delivery system is designed to provide a plasma concentration-time profile, which varies according to physiological need at different times during the dosing period, i.e., mimicking the circadian rhythm and severity / manifestation of gastric acid secretion (and / or midnight gerd), predicted based on pharmaco-kinetic and pharmaco-dynamic considerations and in vitro / in vivo correlations.

The present invention provides a method and composition for treatment of benign prostate hyperplasia (BPH) in men via a transscrotal delivery system. The composition of the present invention includes the steroid hormone progesterone containing permeation enhancers that greatly facilitate permeation through the skin, thus preventing modification of the constituents therein and providing continuous and sustained delivery of progesterone for several hours that mimics the circadian rhythm of endogenous progesterone. The progesterone composition preferably is capable of delivering an effective dosage amount of about 65-100 mg of progesterone per ml when applied directly onto the surface of scrotum.

The present invention involves a light system for stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals based upon the discovery of peak sensitivity ranging from 425-505 nm; a light meter system for quantifying light which stimulates or regulates mammalian circadian, photoneural, and neuroendocrine systems. The present invention also relates to translucent and transparent materials, and lamps or other light sources with or without filters capable of stimulating or regulating neuroendocrine, circadian, and photoneural systems in mammals. Additionally, the present invention involves treatment of mammals with a wide variety of disorders or deficits, including light responsive disorders, eating disorders, menstrual cycle disorders, non-specific alerting and performance deficits, hormone-sensitive cancers, and cardiovascular disorders.

Systems and methods to provide light therapy to a subject use one or more light sources configured to emit electromagnetic radiation in multiple stages using multiple wavelengths. By virtue of the emitted electromagnetic radiation impinging on the subject, the phase of the circadian rhythm of the subject is modified.

The present invention relates to a method and apparatus for increasing the delivery rate of an androgen transdermal therapeutic system through the skin. An androgen transdermal therapeutic system can be applied to a patient's skin for delivery of the androgen. A temperature modification apparatus which is capable of generating controlled heat is applied approximate to the androgen transdermal therapeutic system. The heating from the temperature modification apparatus raises the temperature of the androgen transdermal therapeutic system and raises the temperature of the patient's skin to achieve an increased rate of delivery of androgen through the skin. The controlled heat can also be used to adjust dosage rates of the androgen transdermal therapeutic system and to mimic natural circadian patterns. The controlled heating may also be used to improve or regulate the release of androgen from injected / implanted extended / controlled release systems.

A method of dynamically adjusting a circadian rhythm comprising the steps of determining a current circadian rhythm status of a circadian rhythm of an observer, accessing a calendar of the observer, and identifying a future event of the observer to precondition for, defined as an identified future event. A preconditioning schedule responsive to the identified future event may then be determined. Furthermore, communication with a light source may be established, and the light source may then be operated to emit light according to the preconditioning schedule.

The present invention is to provide a sustained-release preparation which comprises a compound having angiotensin II antagonistic activity, its pro-drug or their salt, and a biodegradable polymer, and if necessary, a polyvalent metal, and which is highly stable and active and shows angiotensin II antagonistic activity while maintaining circadian rhythm of blood pressure for a long time.

The invention discloses an assistant hypoglycemic healthcare biscuit belonging to a healthcare food. The assistant hypoglycemic healthcare biscuit contains the following components which are measuredby grams and shown in a table. The food containing dietary fiber is prepared for diabetes patients to eat, not only complements daily dietary fiber, but also favorably regulates the circadian rhythm,prevents the blood sugar from rising, has the assistant healthcare function for decreasing the cholesterol of the postprandial blood sugar and the fasting blood sugar of the diabetes patients, prevents diseases, promotes rehabilitation and integrates functions, convenience, recreation, and the like into a whole.

A method of maintaining circadian rhythm of a subject comprising selectively substantially blocking retinal exposure of the subject to light having a wavelength shorter than a specified wavelength during the night, and an apparatus for carrying out the claimed method comprising an optical filter that selectively at least substantially blocks light having a wavelength shorter than the specified wavelength.

Systems and methods for treating diseases, addictions and disorders in humans and animals involving synchronizing and tailoring the administration of drug compounds with the body's natural circadian rhythms, in order to counteract symptoms when they are likely to be at their worst. Automated and pre programmable transdermal drug administration system are used. This system can also utilize a pump or pressurized reservoir, and / or a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with micro-fabricated structures commonly referred to as Micro-needles, or heat, or iontophoresis, sonophoresis, or a wide range of chemical permeation enhancers.

This invention relates to a low cost rapid response diagnostic system to determine cortisol levels in patients selected as potential candidates for GCR (glucocorticoid receptor) antagonist therapy utilizing a GCR antagonist, such as ORG 34517. The rapid, sensitive, and inexpensive test can be used to determine patients who have non-normal cortisol production or disordered circadian rhythms as a method for selecting subjects for GCR antagonist therapy for whom it is likely to have beneficial and / or therapeutic effects, and can also be used to monitor changes in cortisol levels in response to treatment.

This invention presents a new method to generate therapeutically superior Bipolar PEMFs while significantly reducing the overall power consumption allowing for the use of low-power coin cell batteries; and presents a new frequency format to be followed for long-duration exposure PEMF Therapy devices. This is accomplished using a battery powered crystal clocked microcontroller and H-Bridge to pulse an electromagnetic inductor with a storage capacitor to generate a positive pulse followed by a shorter negative pulse, followed by some period of no current flowing generating frequencies in support of mammalian Circadian Rhythms.